These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36543540)

  • 21. High or increasing serum NfL is predictive of impending multiple sclerosis relapses.
    Thebault S; Reaume M; Marrie RA; Marriott JJ; Furlan R; Laroni A; Booth RA; Uccelli A; Freedman MS
    Mult Scler Relat Disord; 2022 Mar; 59():103535. PubMed ID: 35078125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    Fujimori J; Nakashima I
    J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis.
    Thebault S; Lee H; Bose G; Tessier D; Abdoli M; Bowman M; Berard J; Walker L; Rush CA; MacLean H; Booth RA; Narayanan S; Arnold DL; Tabard-Cossa V; Atkins HL; Bar-Or A; Freedman MS
    Ann Clin Transl Neurol; 2020 May; 7(5):767-775. PubMed ID: 32304358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.
    Vardakas I; Dorst J; Huss A; Mayer B; Fangerau T; Taranu D; Tumani H; Senel M
    Eur J Neurol; 2024 Aug; 31(8):e16323. PubMed ID: 38700322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
    Sotirchos ES; Vasileiou ES; Filippatou AG; Fitzgerald KC; Smith MD; Lord HN; Kalaitzidis G; Lambe J; Duval A; Prince JL; Mowry EM; Saidha S; Calabresi PA
    Neurology; 2022 Aug; 99(7):e688-e697. PubMed ID: 35618438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Jakimovski D; Zivadinov R; Ramanthan M; Hagemeier J; Weinstock-Guttman B; Tomic D; Kropshofer H; Fuchs TA; Barro C; Leppert D; Yaldizli Ö; Kuhle J; Benedict RH
    Mult Scler; 2020 Nov; 26(13):1670-1681. PubMed ID: 31610732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations.
    Plantone D; Locci S; Bergantini L; Manco C; Cortese R; Meocci M; Cavallaro D; d'Alessandro M; Bargagli E; De Stefano N
    J Neurol Neurosurg Psychiatry; 2022 Dec; 93(12):1343-1348. PubMed ID: 36137741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
    Fissolo N; Benkert P; Sastre-Garriga J; Mongay-Ochoa N; Vilaseca-Jolonch A; Llufriu S; Blanco Y; Hegen H; Berek K; Perez-Miralles F; Rejdak K; Villar LM; Monreal E; Alvarez-Lafuente R; Soylu OK; Abdelhak A; Bachhuber F; Tumani H; Martínez-Yélamos S; Sánchez-López AJ; García-Merino A; Gutiérrez L; Castillo-Trivino T; Lycke J; Rosenstein I; Furlan R; Filippi M; Téllez N; Ramió-Torrentà L; Lünemann JD; Wiendl H; Eichau S; Khalil M; Kuhle J; Montalban X; Comabella M
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):410-418. PubMed ID: 37940409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
    Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K
    Eur J Neurol; 2021 Dec; 28(12):4153-4166. PubMed ID: 34487400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.
    Jakimovski D; Kuhle J; Ramanathan M; Barro C; Tomic D; Hagemeier J; Kropshofer H; Bergsland N; Leppert D; Dwyer MG; Michalak Z; Benedict RHB; Weinstock-Guttman B; Zivadinov R
    Ann Clin Transl Neurol; 2019 Sep; 6(9):1757-1770. PubMed ID: 31437387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
    Li Y; Liu Y; Zhao W; An X; Zhang F; Zhang TX; Liu Y; Du C; Zeng P; Yuan M; Zhang N; Zhang C
    J Neuroimmunol; 2023 Nov; 384():578218. PubMed ID: 37801952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG
    Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
    Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA;
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurofilament Light Chain Serum Levels Mirror Age and Disability in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Study.
    Husseini L; Jung J; Boess N; Kruse N; Nessler S; Stadelmann C; Metz I; Haupts M; Weber MS
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200279. PubMed ID: 38991171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
    Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
    Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinically relevant increases in serum neurofilament light chain and glial fibrillary acidic protein in patients with Susac syndrome.
    Plantone D; Sabatelli E; Locci S; Marrodan M; Laakso SM; Mateen FJ; Feresiadou A; Buelens T; Bianco A; Fiol MP; Correale J; Tienari P; Calabresi P; De Stefano N; Iorio R
    Eur J Neurol; 2023 Oct; 30(10):3256-3264. PubMed ID: 37335505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.